Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
7 Hills Pharma, LLC
Regeneron Pharmaceuticals
Alpha Tau Medical LTD.
Iovance Biotherapeutics, Inc.
University of Thessaly
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Fred Hutchinson Cancer Center
Obsidian Therapeutics, Inc.
Institute of Health Information and Statistics of the Czech Republic
Rhode Island Hospital
Filamon LTD
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ankyra Therapeutics, Inc
Replimune Inc.
University of Florida
Institute of Oncology Ljubljana
Institute of Oncology Ljubljana
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Linkoeping University
Iovance Biotherapeutics, Inc.
Massachusetts General Hospital
OncoNano Medicine, Inc.
Rutgers, The State University of New Jersey
Emory University
University of Oklahoma
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Cancer Research UK
Dana-Farber Cancer Institute
British Columbia Cancer Agency
Rutgers, The State University of New Jersey
Bruce Robinson, MD
University Health Network, Toronto
Medicenna Therapeutics, Inc.
Columbia University
University of Arizona
Stanford University
Algemeen Ziekenhuis Maria Middelares
Alpha Tau Medical LTD.
Wright State University
Hull University Teaching Hospitals NHS Trust
Zealand University Hospital